KEROS THERAPEUTICS INC's ticker is KROS and the CUSIP is 492327101. A total of 81 filers reported holding KEROS THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $20,308 | -74.3% | 637 | -67.6% | 0.00% | -66.7% |
| Q2 2023 | $78,994 | +164470.8% | 1,966 | +72.5% | 0.00% | +50.0% |
| Q1 2023 | $48 | +108.7% | 1,140 | +134.6% | 0.00% | +100.0% |
| Q4 2022 | $23 | -100.0% | 486 | -82.9% | 0.00% | -50.0% |
| Q3 2022 | $107,000 | +7.0% | 2,843 | -21.7% | 0.00% | 0.0% |
| Q2 2022 | $100,000 | +376.2% | 3,632 | +863.4% | 0.00% | – |
| Q1 2022 | $21,000 | -78.6% | 377 | -77.5% | 0.00% | -100.0% |
| Q4 2021 | $98,000 | +415.8% | 1,677 | +246.5% | 0.00% | – |
| Q3 2021 | $19,000 | -55.8% | 484 | -52.1% | 0.00% | -100.0% |
| Q2 2021 | $43,000 | +22.9% | 1,010 | +79.7% | 0.00% | 0.0% |
| Q1 2021 | $35,000 | +150.0% | 562 | +192.7% | 0.00% | – |
| Q4 2020 | $14,000 | -94.3% | 192 | -97.0% | 0.00% | -100.0% |
| Q3 2020 | $247,000 | +1800.0% | 6,399 | +1744.1% | 0.00% | +200.0% |
| Q2 2020 | $13,000 | – | 347 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Fairmount Funds Management LLC | 396,911 | $21,584,000 | 5.10% |
| Deep Track Capital, LP | 1,380,306 | $75,061,000 | 4.81% |
| Opaleye Management Inc. | 265,750 | $14,451,000 | 4.49% |
| Octagon Capital Advisors LP | 340,214 | $18,501,000 | 4.00% |
| First Light Asset Management, LLC | 658,145 | $35,790,000 | 3.16% |
| Altium Capital Management LP | 126,000 | $6,852,000 | 2.29% |
| Nantahala Capital Management | 816,830 | $44,419,000 | 1.96% |
| Orbimed Advisors | 1,679,417 | $91,327,000 | 1.48% |
| CHI Advisors LLC | 62,229 | $3,384,000 | 1.44% |
| Parkman Healthcare Partners LLC | 72,690 | $3,953,000 | 1.16% |